HDL therapy for the acute treatment of atherosclerosis

Atherosclerosis Supplements

Volumn 3, Issue 4, 2002, Pages 31-38

  Newton, Roger S ^a   Krause, Brian R ^a  

^a Esperion Therapeutics Inc   (United States)

Author keywords

Atherosclerosis; Cholesterol efflux; HDL; Reverse lipid transport

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETC 588; ETC 642; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOSOME; LIPOSTABIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE; PHOSPHOLIPID; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTERY; ARTERY WALL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EXPERIMENT; HUMAN; HYPERLIPOPROTEINEMIA; INJECTION; LOW DRUG DOSE; METHODOLOGY; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL VEIN; PRIORITY JOURNAL; TRANSPORT KINETICS; ANIMAL; ARTERIOSCLEROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS, HDL;

EID: 0038690590     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(02)00044-2     Document Type: Conference Paper

References (68)

1. Orekhov A.N., Misharin A.Y., Tertov V.V., Khashimov K.A., Pokrovsky S.N., Repin V.S., et al. Artificial HDL as an anti-atherosclerotic drug. Lancet. II:1984;1149-1150.
2. Hirz R., Scanu A.M. Reassembly in vitro of a serum high density lipoprotein. Biochim. Biophys. Acta. 207:1970;364-370.
3. Bates S.R., Rothblatt G.H. Regulation of cellular sterol flux and synthesis by human serum lipoproteins. Biochim. Biophys. Acta. 360:1974;38-55.
4. American Heart Association. 2002 Heart and Stroke Statistical Update. 2002.
5. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345:2001;494-502.
6. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/ IIIa inhibitor tirofiban. N. Engl. J. Med. 344:2001;1879-1887.
7. Jackson R.L., Gotto A.M., Stein O., Stein Y. A comparative study on the removal of cellular lipids from Landschutz ascites cells by human plasma lipoproteins. J. Biol. Chem. 250:1975;7204-7209.
8. Stein O., Stein Y. The removal of cholesterol from Landschutz ascites cells by high density apolipoprotein. Biochim. Biophys. Acta. 326:1973;232-234.
9. Rothblat G.H., de la Llera-Moya M., Atger V., Kellner-Weibel G., Williams D.L., Phillips M.C. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid. Res. 40:1999;781-796.
10. Francone O.L., Aiello R.J. ABCA1: regulation, function and relationship to atherosclerosis. Current. Opin. Invest. Drugs. 3:2002;415-419.
11. Velez-Carrasco W., Lichtenstein A.H., Li Z., Dolnikowski G.G., Lamon-Fava S., Welty F.K., et al. Apolipoprotein A-I and A-II kinetic parameters as assessed by endogenous labeling with [2H3] leucine in middle-aged and elderly men and women. Arterioscler. Thromb. Vasc. Biol. 20:2000;801-806.
12. Forte T.M., McCall M.R., Amacher S., Nordhausen R.W., Vigne J.L., Mallory J.B. Physical and chemical characteristics of apolipoprotein A-I-lipid complexes produced by Chinese hamster ovary cells transfected within the human apolipoprotein A-I gene. Biochim. Biophys. Acta. 1047:1990;11-18.
13. Walsh A., Ito Y., Breslow J.L. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J. Biol. Chem. 264:1989;6488-6494.
14. Rubin E.M., Ishida B.Y., Clift S.M., Krauss R.M. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. 88:1991;434-438.
15. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 353:1991;265-267.
16. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. 91:1994;9607-9611.
17. Duverger N., Viglietta C., Berthou L., Emmanuel F., Tailleux, Parmentier-Nihoul L., et al. Transgenic rabbits expressing human apolipoprotein A-I in the liver. Arterioscler. Thromb. Vasc. Biol. 16:1996;1424-1429.
18. Duverger N., Kruth H., Emmanuel F., Caillaud J.-M., Viglietta C., Castro G., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 94:1996;713-717.
19. Rea T.J., Bisgaier C.L., DeMattos R.B., Pape M.E. Rabbit liver apolipoprotein A-I synthesis is under nonparenchymal cell paracrine control. J. Lipid. Res. 35:1994;1274-1282.
20. Kopfler W.P., Willard M., Betz T., Willard J.E., Gerard R.D., Meidell R.S. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation. 90:1994;1319-1327.
21. De Geest B., Zhao Z., Collen D., Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 96:1997;4349-4356.
22. Benoit P., Emmanuel F., Caillaud J.M., Bassinet L., Castro G., Gallix P., et al. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation. 99:1999;105-110.
23. Tangirala R.K., Tsukamoto K., Chun S.H., Usher D., Pure E., Rader D.J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 100:1999;1816-1822.
24. Wang Y.-X., Martin-McNulty B., Huw L.-Y., da Cunha V., Post J., Hinchman J., et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 162:2002;23-31.
25. Hayes H.M., Fisher E.A. High-density lipoprotein and plaque regression. The good cholesterol gets even better. Circulation. 100:1999;1762-1763.
26. Linthout V., Collen D., De Geest B. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity, after adenoviral gene transfer of human apolipoprotein A-I. Hum. Gene. Ther. 13:2002;829-840.
27. Reis E.D., Li J., Fayad Z.A., Rong J.X., Hansoty D., Aguinaldo J.G., et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J. Vasc. Surg. 34:2001;541-547.
28. Rong J.X., Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 104:2001;2447-2452.
29. Badimon J.J., Badimon L., Galvez A., Dische R., Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. 60:1989;455-461.
30. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85:1990;1234-1241.
31. Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;1882-1888.
32. Koizumi J., Kano M., Okabayashi K., Jadhav A., Thompson G.R. Behavior of human apolipoprotein A-I: phospholipid and apoHDL:phospholipid complexes in vitro and after injection into rabbits. J. Lipid. Res. 29:1988;1405-1415.
33. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103:2001;108-112.
34. Alam K., Meidell R.S., Spady D.K. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J. Biol. Chem. 276:2001;15641-15649.
35. Chiesa G., Sirtori C.R. Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I. Current. Opin. Invest. Drugs. 3:2002;420-426.
36. Sirtori C.R., Calabresi L., Franceschini G., Baldassare D., Amato M., Johansson J., et al. Cardiovascular status of carriers of the apolipoprotein A-I Milano mutant. The Limone sul Garda Study. Circulation. 103:2001;1949-1954.
37. Calabresi L., Vecchio G., Longhi R., Gianazza E., Palm G., Wadensten H., et al. Molecular characterization of native and recombinant apolipoprotein A-I Milano dimer. J. Biol. Chem. 269:1994;32168-32174.
38. Franceschini G., Calabresi L., Chiesa G., Parolini C., Sirtori C.R., Canavesi M., et al. Increased cholesterol efflux potential of sera from apoA-I Milano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;1257-1262.
39. Soma M.R., Donetti E., Parolini C., Sirtori C.R., Fumagalli R., Franceschini G. Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76:1995;405-411.
40. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., et al. Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97:1998;780-785.
41. Shah P.K., Yano J., Reyes O., Chyu K.-Y., Kaul S., Bisgaier C.L., et al. High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation. 103:2001;3047.
42. Chiesa G., Monteggia E., Marchesi M., Lorenzon P., Laucello M., Lorusso V., et al. Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. 90:2002;974-980.
43. Anantharamaiah G.M. Synthetic peptide analogs of apolipoproteins. Meth. Enzymol. 128:1986;627-647.
44. Labeur C., Lins L., Vanloo B., Baert J., Brasseur R., Rosseneu M. Design of a new class of amphipathic helical peptides for the plasma apolipoproteins that promote cellular cholesterol efflux but do not activate LCAT. Arterioslcer. Thromb. Vasc. Biol. 17:1997;580-588.
45. Buchko G.W., Treleaven W.D., Dunne S.J., Tracey A.S., Cushley R.J. Structural studies of a peptide activator of human lecithin-cholesterol acyltransferase. J. Biol. Chem. 271:1996;3039-3045.
46. Garber D.W., Datta G., Chaddha M., Palgunachari M.N., Hama S.Y., Navab M., et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid. Res. 42:2001;545-552.
47. Navab M., Anantharamaiah G.M., Hama S., Garber D.W., Chaddha M., Hough G., et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105:2002;290-292.
48. Williams K.J., Tall A.R. Interactions of liposomes with lipoproteins: relevance to drug delivery systems and to the treatment of atherosclerosis. Gregoriadis G. Liposomes as drug carriers. 1988;93-111 Wiley.
49. Rodrigueza W.V., Phillips M.C., Williams K.J. Structural and metabolic consequences of liposome-lipoprotein interactions. Advanced Drug Deliv. Rev. 32:1998;31-43.
50. Rodrigueza W.V., Williams K.J., Rothblatt G.H., Phillips M.C. Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler. Thromb. Vasc. Biol. 17:1997;383-393.
51. Rodrigueza W.V., Pritchard P.H., Hope M.J. The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim. Biophys. Acta. 1153:1993;9-19.
52. Williams K.J., Scalia R., Mazany K.D., Rodrigueza W.V., Lefer A.M. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 20:2000;1033-1039.
53. Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., et al. Effects of intravenous infusion of lipid-free apoA-I in humans. Arterioscler. Thromb. Vasc. Biol. 16:1996;1203-1214.
54. Nanjee M.N., Doran J.E., Lerch P.G., Miller N.E. Acute effects of intravenous infusion of apoAI/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19:1999;979-989.
55. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 100:1999;594-598.
56. Westman J., Roobol C., Heymans C., Carlson L.A., Wulfert E. Efflux of cholesterol from cholesterol loaded macrophages by incubation with synthetic HDL particles. Scand. J. Clin. Invest. 53:1993;773-782.
57. Nanjee M.N., Cooke C.J., Garvin R., Semeria F., Lewis G., Olszewski W.L., et al. Intravenous apoA-I/lecithin discs increase pre-β-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid. Res. 42:2001;1586-1593.
58. Menke J.G., Macnaul K.L., Hayes N.S., Baffic J., Chao Y.-S., Elbrecht A., et al. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7a-hydroxylase (CYP7a). Endocrinology. 143:2002;2548-2558.
59. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 105:2002;1399-1402.
60. Cole T.G., Nowatzke W.L., Bisgaier C.L., Krause B.R. Method-dependent changes in 'HDL-Cholesterol' with recombinant apolipoprotein A-I Milano infusion in healthy volunteers. Clin. Chem. 48:2002;680-681.
61. Esperion Therapeutics, Inc. News Release. Available from http://www.esperion.com , Dec. 4, 2001.
62. Esperion Therapeutics, Inc. News Release. Available from http://www.esperion.com , July 15, 2002.
63. Blaton V., Soetewey F., Vandamme D., Declercq B., Peeters H. Effect of polyunsaturated phophatidylcholine on human types II and IV hyperlipoproteinemias. Artery. 2:1976;309-325.
64. Williams K.J., Werth V.P., Wolff J.A. Intravenously administered lecithin liposomes: a synthetic antiatherosclerotic lipid particle. Perspect. Biol. Med. 27:1984;417-431.
65. Rodrigueza W.V., Mazany K.D., Essenburg A.D., Pape M.E., Rea T.J., Bisgaier C.L., et al. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;2132-2139.
66. Rader DJ, Rodrigueza WV, Lalwani ND and Valiquett TR. Infusion of large unilamellar vesicles (ETC-588) mobilizes unesterified cholesterol in a dose-dependent fashion in healthy volunteers and patients with atherosclerosis. Presented at the Third Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UT, April, 2002.
67. Esperion Therapeutics, Inc. Press Release. Available from http://www.esperion.com , June 27, 2002.
68. Rioufol G., Finet G., Ginon I., Andre-Fouet X., Rossi R., Vialle E., et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome. A three-vessel intravascular ultrasound study. Circulation. 106:2002;804-808.